Cara Therapeutics (CARA) Misses Q1 EPS by 7c

Cara Therapeutics (NASDAQ: CARA) reported Q1 EPS of ($0.81), $0.07 worse than the analyst estimate of ($0.74). Revenue for the quarter came in at $843 thousand versus the consensus estimate of $150 thousand.

For earnings history and earnings-related data on Cara Therapeutics (CARA) click here.

You May Also Be Interested In

• Greenbrier Cos. (GBX) Reports In-Line Q3 EPS
• Trump discloses over $1.4 billion in crypto income in 2025 filing
• Constellation Brands (STZ) Tops Q1 EPS by 18c